United States - English - NLM (National Library of Medicine)

bryant ranch prepack - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine hydrobromide extended-release capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type. galantamine hydrobromide extended-release capsules are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of galantamine hydrobromide extended-release capsules in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unkn

Malta - English - Medicines Authority

rosemont pharmaceuticals limited rosemont house, yorkdale industrial park, braithwaite street, leeds ls11 9xe, united kingdom - galantamine hydrobromide - oral solution - galantamine hydrobromide 4 mg - psychoanaleptics

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine hydrobromide extended-release capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type. galantamine hydrobromide extended-release capsules are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of galantamine hydrobromide extended-release capsules in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unkn

Malta - English - Medicines Authority

syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - galantamine hydrobromide - oral solution - galantamine hydrobromide 4 mg/ml - psychoanaleptics

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 20.504 mg (equivalent: galantamine, qty 16 mg) - capsule, modified release - excipient ingredients: hypromellose; gelatin; ethylcellulose; microcrystalline cellulose; iron oxide red; titanium dioxide; magnesium stearate - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: magnesium stearate; gelatin; ethylcellulose; microcrystalline cellulose; titanium dioxide; hypromellose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 30.756 mg (equivalent: galantamine, qty 24 mg) - capsule, modified release - excipient ingredients: iron oxide yellow; hypromellose; magnesium stearate; titanium dioxide; microcrystalline cellulose; iron oxide red; gelatin; ethylcellulose; erythrosine; indigo carmine - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide -